NaV1.8

News

Lilly takes on Vertex in non-opioid pain with SiteOne buy

Lilly buys SiteOne in a $1bn deal that would give it a rival to Vertex's approved painkiller Journavx, and a partnership on another programme.

News

Illustration of a nerve cell on a colored background with light effects

Vertex Pharma makes progress in quest for non-opioid pain dr...

The search for an alternative to opioid drugs for pain relief has dragged one for decades, with little success, but Vertex Pharma thinks that could be about to change. The company

News

UK's Mission divests kidney drug to Dimerix for $292m

Mission Therapeutics has struck a deal to out-license a drug for acute kidney injury to Australia's Dimerix, sharpening its focus on CNS diseases.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks